Compare Amylx Pharmaceuticals Inc (AMLX) vs Dollar General Corp. (DG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Dollar General Corp. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.2 (market cap $1.98B), while Dollar General Corp. trades at $122.99 (market cap $26.23B). The key difference: Dollar General Corp. is far larger — about 13.2× Amylx Pharmaceuticals Inc's market cap, and Dollar General Corp. pays a 1.98% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | DG | |
|---|---|---|
Market Cap | $1.98B | $26.23B |
Sector | Health | Consumer Staples |
52-Week High | $18.70 | $156.26 |
52-Week Low | $7.64 | $95.94 |
Enterprise Value | $1.70B | $40.68B |
Dividend Yield | — | 1.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Dollar General (DG) trades at $118.92, up 2.76% today, with a neutral technical signal and bearish moving averages. The stock shows strong valuation metrics with a P/E of 16.82 and P/S of 0.61, supported by three consecutive quarterly earnings beats. Revenue grew to $40.61B in 2025, though net margins compressed to 2.77%. Positive news highlights margin expansion and back-to-school initiatives, while cash flow improved to $395M net.
Outlook remains cautiously optimistic with a $128.45 consensus price target implying 8% upside. Risks include margin pressure from inflation and competitive threats. Analyst consensus is 52% Buy, but weak consumer sentiment and technical resistance near $120 may limit near-term gains. Debt reduction trends and dividend coverage provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →
